{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ebe8cc563e3d811bbd2c9d8/6ac4d80522e4cb85bd997ba6?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"IMS 2026 | UKMRA ProMMise D interim results: VRAT-guided belantamab mafodotin dosing in RRMM ","description":"<p>During the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK, the Multiple Myeloma Hub spoke with Rakesh Popat, University College Hospital, London, UK. We asked about interim results from Arm D of the UKMRA ProMMise trial in patients with relapsed/refractory multiple myeloma (RRMM). </p><p>In this interview, Popat discusses interim results from Arm D of the ProMMise trial, which is evaluating a vision-related anamnestic tool (VRAT) to assess ocular symptoms and function, and guide belantamab mafodotin dosing in patients with RRMM receiving belantamab mafodotin + bortezomib + dexamethasone (BVd). Popat reviews interim results from Stage 1, including the correlation between VRAT and ocular assessments, and outlines the planned evaluation of VRAT-guided dosing without mandated ocular examinations in Stage 2. </p><p>Intended for healthcare professionals. This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. </p>","author_name":"Scientific Education Support"}